Enteris BioPharma to Attend American Association of Pharmaceutical Scientists (AAPS) PHARMSCI 360 Conference 2021

Posted: October 13, 2021 at 7:30 a.m. CDT|Update: 15 minutes ago

BOONTON, New JerseyOct. 13, 2021 / PRNewswire / – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), has announced today that the company will attend the 2021 American Association of Pharmaceutical Scientists (AAPS) PHARMSCI 360 conference to be held 17-20 October 2021 to Pennsylvania Congress center in Philadelphia cream. This year’s meeting includes in-person and virtual participation options.

During the conference, members of the Enteris leadership team will host virtual and in-person meetings with pharmaceutical executives to explore opportunities involving Peptelligence.® and ProPerma®, the company’s new formulation technologies that enable oral delivery of BCS Class III and IV compounds including peptides, peptidomimetics, small molecules, as well as recent contract development and manufacturing (CDMO) operations launched by the company and its expanded manufacturing facility. Enteris continues to advance internal and external programs that rely on Peptelligence and ProPerma, some of which are in advanced clinical development.

Rajiv khosla, Ph.D., CEO of Enteris, said: “Since launching our CDMO operations and completing our expanded manufacturing facility earlier this year, we have had the opportunity to engage numerous pharmaceutical companies. who require our highly specialized drug development and manufacturing services. , including high power API containment production (HPAPI). offerings during APSA. “

About Enteris BioPharma
Enteris BioPharma, Inc. is a wholly owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH) providing integrated contract development and manufacturing (CDMO) services, including innovative formulation solutions using its proprietary technologies for delivering drugs, Peptelligence® and ProPerma ™. The technologies have been the subject of numerous feasibility studies and active development programs, many of which are in clinical development. In addition, Enteris BioPharma is developing an innovative internal pipeline of drug products that address significant unmet clinical needs for which there are no satisfactory treatment options. For more information on Enteris BioPharma and its proprietary oral delivery technology, please visit www.EnterisBioPharma.com.

Show original content:

SOURCE Enteris BioPharma, Inc.

The above press release has been provided courtesy of PRNewswire. The views, opinions and statements contained in the press release are not endorsed by Gray Media Group and do not necessarily state or reflect those of Gray Media Group, Inc.

About Tina G.

Check Also

Movement Industries Corporation Expands National Reach With New Contracts

Company expands to support Gulf of Mexico LNG platforms Houston, Texas – (NewMediaWire) – October …